Literature DB >> 12853756

Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy.

Charles J L la Porte1, Jan-Christian Wasmuth, Katrin Schneider, Jürgen K Rockstroh, David M Burger.   

Abstract

Patients receiving a lopinavir/ritonavir and saquinavir dual protease inhibitor-based antiretroviral salvage regimen were studied to evaluate the pharmacokinetics, tolerability and efficacy of the regimen. Pharmacokinetic curves were obtained for lopinavir and saquinavir. Patient records were studied for adverse events and efficacy data. The pharmacokinetics of lopinavir and saquinavir were comparable with literature data, except for the saquinavir 0-12 h area under the curve and maximum concentration. The tolerability of the regimen was good and efficacy was encouraging.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853756     DOI: 10.1097/00002030-200307250-00018

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

1.  Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.

Authors:  Regina B Osih; Patrick Taffé; Martin Rickenbach; Angèle Gayet-Ageron; Luigia Elzi; Christoph Fux; Milos Opravil; Enos Bernasconi; Patrick Schmid; Huldrych F Günthard; Matthias Cavassini
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

2.  Virologic efficacy of boosted double versus boosted single protease inhibitor therapy.

Authors:  Maya L Petersen; Yue Wang; Mark J van der Laan; Soo-Yon Rhee; Robert W Shafer; W Jeffrey Fessel
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

Review 3.  Double-boosted protease inhibitor antiretroviral regimens: what role?

Authors:  Esteban Ribera; Adrian Curran
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir.

Authors:  Amanda H Corbett; Kristine B Patterson; Hsiao-Chuan Tien; Leslie A Kalvass; Joseph J Eron; Linh T Ngo; Michael L Lim; Angela D M Kashuba
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.

Authors:  Elena Seminari; Monica Guffanti; Paola Villani; Nicola Gianotti; Maria Cusato; Giuliana Fusetti; Andrea Galli; Antonella Castagna; Mario Regazzi; Adriano Lazzarin
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

6.  Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Authors:  Esteban Ribera; Rosa M Lopez; Marjorie Diaz; Leonor Pou; Lidia Ruiz; Vicenç Falcó; Manuel Crespo; Carlos Azuaje; Isabel Ruiz; Imma Ocaña; Bonaventura Clotet; Albert Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Authors:  Brian L Robbins; Edmund V Capparelli; Ellen G Chadwick; Ram Yogev; Leslie Serchuck; Carol Worrell; Mary Elizabeth Smith; Carmelita Alvero; Terence Fenton; Barbara Heckman; Stephen I Pelton; Grace Aldrovandi; William Borkowsky; John Rodman; Peter L Havens
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

Review 8.  Current and future antiretroviral treatment options in paediatric HIV infection.

Authors:  Carlo Giaquinto; Erika Morelli; Federica Fregonese; Osvalda Rampon; Martina Penazzato; Anita de Rossi; Ruggero D'Elia
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.